Azevan Pharmaceuticals   Report issue

For profit Phase 1 Phase 2
Founded: Bethlehem PA United States (1999)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2007
NCT00461370
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

srx-246 (6 trials)

Drugs in Phase 1 Trials (1)

srx-251 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 1)

Disease (Phase 2)

Disruptive, Impulse Control, and Conduct Disorders (Phase 2)

Huntington Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 2